Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Causes of Death in US Adults With a COPD Diagnosis, An Analysis of the US National Vital Statistics System
Scrodin, M. Dulohery, Harris, B.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5324-A5324

10.1164/ajrccm.2025.211.abstracts.a5324 Get It

Abstract Introduction: Chronic obstructive pulmonary disease (COPD) is a top 5 cause of death and bears significant morbidity and mortality. The role of multimorbidity in patients with COPD has been shown to affect quality of life, increase risk of disease exacerbation, and mortality. COPD-targeted treatments have shown limited effects on mortality, but this patient population may benefit from practitioners more aggressively managing other comorbid conditions. Understanding which diseases have the largest impact on mortality in COPD patients may help providers understand which comorbidities to manage aggressively. Methods: We used the National Vital Statistics System (NVSS; 2019 data release), which collects all death certificate data for US citizens along with basic demographic information. We only included those who died with COPD as a diagnosis on their death certificate, defined as those who had international classification of disease, version 10 (ICD-10) codes J40-J44. We then dichotomized the causes of death by COPD vs non-COPD causes, based on the underlying cause of death (UCOD) on the death certificate. UCOD is defined by the NVSS as “the disease or injury which initiated the train of events leading directly to death.” Demographic information was collected, race was self-reported, and level of education was dichotomized as less than HS diploma vs higher. We used chi-square or t-test to determine statistical significance (defined as p <0.05) between groups for demographic information. Results: 308,856 US adults had an ICD-10 code associated with COPD written on their death certificate, of these 156,499 (50.6%) had a UCOD other than COPD. Overall, mean age 77.1 years (SD 2.6 years), 49% were female. The 10 most common diagnoses of those who died of non-COPD causes are presented in Figure 1, with the three most common causes being lung cancer (23689, 15.1%), atherosclerotic heart disease (22,848, 14.6%), and acute myocardial infarction (6422, 4.1%). Six of the top 10 are cardiovascular diseases. Conclusion: Patients with COPD are at high risk of mortality from comorbid conditions, with around 50% dying from non-COPD etiologies according to death certificate data. Most of these etiologies have evidence-based and mortality-reducing interventions such as lung cancer screening and management of cardiovascular risk factors including cholesterol-lowering medications and antihypertensives. While we don't have more granular data in terms of medications and therapies, these findings suggest that guideline-oriented approaches, both in terms of lung cancer screening and cardiovascular-risk reduction, may have a strong impact on mortality reduction in this patient population.
Misadventures in Vaping Cessation: A Qualitative Study Demonstrating Social Media as a Highly Utilized Source of Health Advice and Misinformation
Rusk, A.M., Ishimoto, A., Varghese, C., Kennedy, Cassie C.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5319-A5319

10.1164/ajrccm.2025.211.abstracts.a5319 Get It

Abstract Introduction: Over 90% of adolescents (18-24 years) have a social media account. In 2021, an estimated 18.3% of 18-24-year-olds used electronic cigarettes. This age group is more likely to use social media as a health information resource than other sources. The social media platform TikTok is the fastest growing platform among adolescents. There is growing interest in vaping cessation among adolescents, and vaping cessation posts have grown accordingly. Our hypothesis is there are diverse vaping cessation methods described by TikTok users important for clinicians to understand. The use of qualitative methods informed by netnography represents an ideal way to evaluate TikTok videos. Methods: TikTok videos describing at least one vaping cessation method posted in English uploaded after January 1, 2022 were eligible for inclusion. Any post associated with advertising, sponsorship, corporations, or retail entities were excluded. Reposts of any kind were excluded. A total of 200 videos were reviewed in duplicate for eligibility. NVivo Version 14 transcription cloud and coding software was used. Coding was conducted independently by the study team until thematic saturation was reached. This study was deemed exempt by the Mayo Clinic Institutional Review Board as social media data is public domain and no identifiers were collected. Results: A total of 52 videos were included. Included videos had an average of 2.4 million views, 285,000 likes, and 11,000 shares. There were a wide variety of vaping cessation methods described. Some methods, such as hand motions mimicking vaping, limiting exposures, and use of nicotine replacement are supported by cigarette smoking cessation literature. There were also numerous videos outlining methods known to be ineffective or harmful, including instructions to vape continuously until illness occurs, and utilizing negative self-affirmations to “scold” yourself when using electronic cigarettes. Themes of inner strength, motivations, and shame were also discussed, and multiple users described their “wake up call” to quit vaping. Conclusions: Social media platforms are growing in popularity with adolescents and individuals under age 18. The inability for users to discriminate between evidence-based health advice and anecdotal experiences represents a key issue for clinicians to be aware of when counseling patients. Given the age demographics of social media users, this issue will grow as the population ages. Clinicians should engage in conversations with their patients about sources of reputable health information, and future directions may include novel methods such as partnering with influencers or social media companies.
New Onset Atrial Fibrillation in Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, and Overlap Syndrome: A Retrospective Observational Study from the Trinetx Database
Hoffer, M., Kanaan, Camille, Soin, S., Pham, H.N., Adkins, Arlie , Kanaan, C., Mahmoud, M., Ibrahim, R.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5315-A5315

10.1164/ajrccm.2025.211.abstracts.a5315 Get It

Abstract RATIONALE:New-onset atrial fibrillation (NOAF) is a common arrhythmia associated with adverse outcomes in patients with chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). Both conditions, through shared mechanisms, raise the likelihood of NOAF incidence, emphasizing the importance of epidemiological data and preventive measures to prevent NOAF burden. Therefore, we examined the risk of NOAF in patients with COPD, OSA, and their overlap syndrome (OS). METHODS: We extracted data from the Banner Healthcare Organization, US Collaborative Network in TriNetX, identifying three patient cohorts using ICD-10 codes for COPD (J40-J44) and OSA (G47.3). This included 73,540 patients with OS, 198,880 patients with OSA only, and 337,010 patients with COPD only. Patients with a prior diagnosis of AF before their diagnosis of OSA or COPD were excluded. Propensity matching was conducted based on age, sex, ethnicity, and cardiovascular disease risk factors and prevalence including hypertension, tobacco use, dyslipidemia, obesity, and ischemic heart disease. We calculated the relative risk (RR), hazard ratio (HR), and 95% confidence intervals (CI) for incident AF among propensity score-matched cohorts, comparing OS with OSA alone and OS with COPD alone.RESULTS: In the OS vs. OSA only comparison, 63,070 patients were matched per cohort. Lifetime incidence of new AF was higher in the OS group (13.65%) compared to the OSA-only group (8.24%), with an RR of 1.66 [95% CI: 1.60-1.72]. Kaplan-Meier analysis indicated a lower AF-free probability in the OS group (65.96%) than in the OSA-only group (77.03%), with an HR of 1.56 (p < 0.001). In the OS vs. COPD only comparison, 65,810 patients were matched per cohort. Incidence of new AF in the OS group was 13.76%, compared to 9.86% in the COPD-only group, with an RR of 1.40 [95% CI: 1.35-1.44]. Kaplan-Meier analysis showed a lower AF-free probability for the OS group (66.13%) versus the COPD-only group (78.94%), with an HR of 1.28 (p < 0.001). Sensitivity analyses restricted to the first five years post-diagnosis revealed a persistently higher relative risk of incident AF in OS patients, with an RR of 1.67 [95% CI: 1.60-1.73] compared to OSA alone, and an RR of 1.34 [95% CI: 1.29-1.39] compared to COPD alone. CONCLUSION:We identified that patients with OS have a higher risk of NOAF compared to either condition alone. This emphasizes the need for vigilant monitoring and targeted interventions in patients with OS to decrease arrhythmogenicity risks.
AP1 Regulates the Expression of Aryl Hydrocarbon Receptor in Asthmatic Airway Smooth Muscle
Reza, M.I., Balraj, Premanand , Tandberg, Cheyenne, Walum, Joshua , Prakash, Y.S., Pabelick, C.M., Britt, Rodney D. , Prakash, Y. S. , Pabelick, C.M., Sathish, Venkatachalem

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5283-A5283

10.1164/ajrccm.2025.211.abstracts.a5283 Get It

Abstract Rationale: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor and cellular chemical sensor. AhR maintains cellular homeostatsis in respons to endogenous and exogenous organic molecules. Airway smooth muscle (ASM) cells are major structural cells in airway which is involved in characteristic features of asthma such as increased airway wall thickness, airway remodeling and airway hyperresponsiveness. Previously, we found notable expression of AhR in human ASM and its increased expression during inflammation and asthma. However, the mechanisms of enhanced AhR expression in ASM is unknown. Therefore, we examined the role of pro-inflammatory signaling pathways in enhanced AhR expression. Methods: Primary human non-asthmatic and asthmatic ASM cells isolated from surgical lung resections (Mayo IRB approved) were cultured in DMEM-F12 medium supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic. At ∼80% confluency, cells were serum deprived and treated with TNFα (20 ng/mL), IL13 (50 ng/mL) with or without PI3K/Akt inhibitor (Wortmannin: 50 nM), p38 inhibitor (SB203580: 600 nM), NFkB inhibitor (SN50 20 μM), and AP1 inhibitor (SR11302 10 μM). Subsequently, expression of AhR was determined using RNA sequencing, confocal microscopy, real-time qPCR, and Western blotting. AhR expression in isolated ASM fron lung tissue section was determined using laser capture microdissection (LCM). Moreover, role of AP1 in inducing AhR expression was confirmed using c-JUN (AP1) siRNA transfection in ASM cells. Additionally, binding of AP1 to the AhR promoter region was demonstrated by chromatin-immunoprecipitation (ChIP-qPCR) technique. Results: AhR expression was significantly high in asthmatic ASM cells and tissue than non-asthmatics. Exposure to pro-inflammatory cytokine TNFα increased AhR mRNA and protein expression, whereas IL-13 failed to do so. Furthermore, inhibition of p38 significantly reduced AhR expression whereas PI3K inhibition had no effect, indicating a role for p38 in AhR increased expression. AP1 inhibition significantly downregulated AhR, while NFkB inhibition showed no effect. Similarly, siRNA mediated silencing of c-JUN (AP1) also downregulated AhR, indicating AP1 role in AhR upregulation. Furthermore, transcription factor binding study suggested AhR promoter region has binding site for AP1 and NFkB. Interestingly, ChIP-qPCR study confirmed binding of AP1 at AhR promote region in response to TNFα. Conclusions: Collectively, the current study show that pro-inflammatory cytokine TNFα increases AhR expression through p38-AP1 pathway. The data shows that pro-inflammatory cytokines can regulate AhR expression in ASM, suggesting AhR in ASM has a role in asthma.
Epigenomic and Transcriptomic Regulation of the MUC5B/MUC5AC Locus in Bronchial Airway Epithelium and Association With Early Small Airways Disease in Spiromics
Ortega, Victor E. , Chen, Xinyi , Shrivastav, A.K. , Zein, Joe , Howard, Timothy D. , Hawkins, Gregory A., Bowler, R.P., Comellas, Alejandro P. , Cooper, C.B. , Galbán, Craig J. , Hansel, Nadia N. , Hastie, Annette T. , Kanner, Richard E. , Martinez, F.J., Paine, Robert , Hoffman, E.A., Meyers, Deborah A. , Woodruff, P., Curtis, J.L., Bleecker, E.R., Christenson, S., C, NHLBI Subpopulations and Intermediate Outcomes Measures in, Christenson, Stephanie A. , Comellas, Alejandro P , Christenson, Stephanie A , Shrivastav, A.K., Barjaktarević, Igor , Barr, R. Graham , Couper, David , Han, MeiLan King , Kaner, Robert J. , Martinez, F.J., O’Neal, Wanda K. , Hoffman, E.A., Curtis, J.L., Huang, Yvonne J

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5245-A5245

10.1164/ajrccm.2025.211.abstracts.a5245 Get It

Abstract Rationale: MUC5B and MUC5AC are neighboring genes on chromosome 11p15 that encode the two predominant mucins secreted in the respiratory airways. Increased airway mucin concentrations and an imbalance between these two mucins drive COPD symptoms and the development of airflow obstruction or COPD, but the epigenomic regulation of this loci has not been characterized in the airways. Methods: We isolated DNA from bronchial airway brushings of 72 participants with >20 pack-years smoking history from the Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS). 36 participants had GOLD-based moderate-to-severe COPD (FEV1/FVC<0.70, FEV1<80%) and 36 were without or with mild COPD. We used the Illumina Infinium Methylation EPIC BeadChip Array to assess proportion of DNA methylation (β) spanning 689,937 CpG sites. We evaluated proportional DNA methylation (β) at 96 CpG loci within a 103kB region using matrixQTL for cis-expression quantitative trait methylation (eQTM: 10kB flanks relative to MUC5AC/MUC5B) integrating bulk RNA-seq data and mQTL models integrating gene sequencing data to identify DNA variation associated with proportion eQTM methylation. Models included age, sex, BMI, clinical site, current smoking vs past smoking, total pack-years, three ancestral components of ancestry, chipset, and position. Results: We identified a top eQTM, cg00524486, marginally associated with MUC5B expression (coefficient estimate=8.75, punadjusted=0.0014, pFDR=0.065, Figure 1B). This eQTM was associated with CT scan parametric response mapping-based functional small airways disease (PRM-fSAD, beta coefficient[β]=3.64, p=0.011). We tested for DNA variation associated with methylation of this top eQTM which identified two methylation quantitative trait loci (mQTL: rs885454 [β=0.044, minor allele frequency[MAF]=0.09, pFDR=0.01], rs868902 [β=0.020, MAF=0.43, pFDR=0.08, Figure 1A) associated with cg00524486 methylation, of which the more frequent mQTL, rs868902, was marginally associated with PRM-fSAD (p=0.07) in the larger SPIROMICS cohort with MUC5B DNA sequencing data. Conclusions: This preliminary multi-omic study of the lower airway epithelium demonstrates that the expression of MUC5B is epigenetically regulated by neighboring CpG probe methylation (eQTM) represented by DNA variation (mQTL). These studies require further confirmation in a larger dataset of airway samples and support a role for epigenetic variation as a biologic contributor and biomarker of early COPD pathogenesis.
Closed Loop, Full Automation of Suspicious Lung Nodule Risk Assessment With AI in Screening Cases
Taha, Abtahir Rahim, Reisenauer, Janani , Kalra, A., Muelly, M. , Reicher, Joshua , Kalra, Angad

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5226-A5226

10.1164/ajrccm.2025.211.abstracts.a5226 Get It

Abstract RATIONALE: Research since 2017 has highlighted artificial intelligence (AI)-based technologies to assist in detecting and/or classifying lung nodules on Computed Tomography (CT) scans. However, few have combined detection and classification tasks, and most have required extensive hands-on image manipulation to process the cases, which is both costly and time-consuming. Here, we present a closed loop, fully automated software package, Bronchosolve, which handles cases from scan to result without manual intervention. METHODS: The software package combined pre-processing, analysis, and result generation system including a deep learning convolutional neural network (CNN) for assessment of suspicious pulmonary nodules. Model inputs were full CT cases formatted in Digital Imaging and Communications in Medicine (DICOM), without demographics or clinical variables. Automated steps included 1) automatic selection of the optimal CT series for analysis; 2) normalization and pre-processing of the series; 3) AI-based analysis of the images to both detect and classify suspicious lung lesions; and 4) generation of analysis report. The system was trained using a multi-center dataset of over 2,358 cases of suspicious lung nodules, including cancers and non-cancers. A United States-based, multi-site cohort (n=184) was used for initial algorithm validation where positive cases were defined as biopsy-proven cancer within 1 year, and negatives as negative biopsy or 2+ year negative follow-up. RESULTS: In the validation set, the system achieved a technical completion rate of 100%, automatically for all cases. Median patient age was 62.5 years (interquartile range 58.5 to 66.5 years), 45% were former smokers, 55% were current smokers, and 40% were female. The AI cancer risk (CA-risk) model achieved an area under the receiver-operating-characteristic curve (AUC) of 0.828 [CI: 0.773 – 0.883] in differentiating cancer from non-cancer in cases with known suspicious pulmonary nodules, as confirmed by biopsy, surgery, and/or follow-up. These results were statistically superior to Lung-RADS pAUC of 0.669 [CI: 0.601 – 0.737] and trended better than Brock model AUC of 0.783 [CI: 0.723 – 0.842], Figure 1. At the Youden operating point, model sensitivity was 73.1% [CI: 66.7 – 79.5%], and specificity was 82.5% [CI: 77.0 – 88.0%]. The model's performance was consistent across various CT scanner manufacturers and tested slice thickness. CONCLUSIONS: The closed loop, automated software system, Bronchosolve, consistently processed and analyzed a wide range of CT scans, providing accurate assessment in risk-classifying suspicious lung nodules. This approach has the potential to improve non-invasive assessment of lung nodules eliminating the need for additional user training and time.
Fellow Perspectives on Interprofessional Teaching in the ICU: A Multicenter Qualitative Study
Theodore, Miranda, Beltran, Christine P. , Herzog, T., Kearney, L. , Maccarone, Jennifer , Pandya, Krishna , Smith, Timothy L. , Anandaiah, Asha , Petri, Camille R. , Bateman, Marjorie , Herzog, T., John, M.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5052-A5052

10.1164/ajrccm.2025.211.abstracts.a5052 Get It

Abstract Rationale : Interprofessional providers (IPPs), such as nurses, pharmacists, and respiratory therapists, teaching physician trainees (“interprofessional teaching” [IPT]), may improve teamwork and quality of care in the intensive care unit (ICU). However, the role that IPPs play in physician trainee education in the ICU and their attitudes about IPT have not been well described. In this study, we explored the impact of IPPs on education for Pulmonary and Critical Care fellows and their perceptions regarding IPPs as teachers for medical trainees. Methods: Fellows from eight large academic medical centers with pulmonary and critical care fellowship programs located in the Northeast, Mid-Atlantic, Midwest and West Coast were invited to participate. Eligible participants included Internal Medicine-trained Pulmonary and Critical Care or Critical Care Medicine fellows in the first, second, or third year of fellowship training. All focus groups were led by a single study team member who facilitated sessions in-person at four sites and virtually at four sites. Focus group transcripts were analyzed using a framework approach, and inter-rater reliability testing was performed prior to coding each manuscript in full (Cohen's kappa = 0.77). Results: Focus groups were held at eight sites between March and July 2023. A total of 50 fellows participated, including 13 first year, 21 second year, and 12 third year fellows, all of whom had completed at least 8 weeks of medical ICU rotations during fellowship. Several themes emerged. Fellows identified the relevance of IPP teaching content, fellow bandwidth to learn from IPPs, and the perceived benefit of relationship building with IPPs as factors that made them ideal learners for IPT among medical trainees. Fellows described distinct teaching content from each IPP group, with nurses revealing the “hidden curriculum,” pharmacists providing specific concrete learning points and incorporating primary literature, and respiratory therapists teaching at the bedside. Identified barriers to IPT included fellows’ competing roles as both teacher and learner in limited time, IPPs having difficulty identifying learner needs at varying levels, and fellows’ uncertainty about whether IPPs view themselves as educators. Conclusions: Fellows are uniquely situated to learn from IPPs in the ICU. Perceived benefits include expansion of their knowledge base and fostering relationships with the interprofessional team. The unique teaching profiles of each IPP group could be leveraged to enhance IPT in the ICU.
Two-year Efficacy and Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Terrier, B., Hellmich, B., Specks, U., Sjö, Lena Börjesson, Ho, C.N. , Jison, Maria, McCrae, Christopher , Necander, S., Rodríguez‐Suárez, Eva, Shavit, A., Wechsler, Michael E , Nair, Parameswaran K. , Khalidi, Nader , Terrier, Benjamin , Bourdin, Arnaud , Jayne, David , Jackson, David J. , Roufosse, Florence , Pagnoux, Christian , Specks, Ulrich , Shavit, Anat , Walton, C., Merkel, Peter A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5029-A5029

10.1164/ajrccm.2025.211.abstracts.a5029 Get It

Abstract Rationale: The 1-year double-blind period of the MANDARA trial (NCT04157348) demonstrated non-inferiority of benralizumab to mepolizumab for achieving remission, in adults with relapsing/refractory eosinophilic granulomatosis with polyangiitis (EGPA). Here, we report the 2-year combined double-blind and ongoing open-label extension (OLE) data. Methods: On completion of the double-blind period (n=136/140) comparing benralizumab 1x30mg versus mepolizumab 3x100mg subcutaneously every 4 weeks, patients were invited to enter the OLE where they continued benralizumab (benra/benra) or switched from mepolizumab to benralizumab (mepo/benra). Endpoints included remission (Birmingham Vasculitis Activity Score=0 and oral glucocorticoid [OGC[ dose ≤4 mg/day), OGC use, relapse, blood eosinophil count (bEOS), Asthma Control Questionnaire (ACQ-6), pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV1), and safety. Results: In total, 128 patients entered the OLE (n=66 benra/benra, n=62 mepo/benra; mean age 52.8 years; 60.2% female), and 119 completed OLE Year 1. Baseline characteristics of those entering the OLE were similar to the double-blind period. At Week 104, over 60% in both groups (41 [62.1%] benra/benra and 42 [67.7%] mepo/benra patients) achieved remission. During the OLE, 51 (77.3%) benra/benra and 42 (67.7%) mepo/benra patients had no relapses. The percentage of benra/benra patients who discontinued OGCs was similar at Weeks 49-52 (27 [40.9%]) and Weeks 101-104 (29 [43.9%]), while the percentage increased for mepo/benra patients between Weeks 49-52 (16 [25.8%]) and Weeks 101-104 (27 [43.5%]; Figure). The median (IQR) OGC dose at Weeks 101-104 was 0.5 (0,5) in benra/benra and 1.36 (0,5) mg/day in mepo/benra patients. The median (IQR) bEOS in benra/benra patients was 20 (10,40) cells/µL at both Weeks 52 and 100; bEOS were depleted in mepo/benra patients from 70 (40,90) cells/µL to 20 (10,50) cells/µL by 4 weeks after switching. Mean (SD) ACQ-6 scores were 0.64 (0.78) in benra/benra patients and 0.60 (0.76) in mepo/benra patients at Week 104 compared with 1.39 (1.18) and 1.11 (0.95) at baseline. Mean (SD) pre-BD FEV1 was 2.59 (0.90) L versus 2.62 (0.84) L in benra/benra versus mepo/benra patients at Week 52, and 2.61 (0.90) versus 2.63 (0.81) L, at Week 100. Safety of mepolizumab and benralizumab was consistent with their known profiles. Conclusions: In patients with EGPA receiving benralizumab, remission rates, OGC discontinuation, and bEOS depletion were durable over 104 weeks with low relapse rates, and without loss of asthma control or lung function decline. Additional bEOS depletion and OGC sparing was observed in patients switching from mepolizumab to benralizumab.
Proteomics of CT Emphysema Subtypes in the General Population. The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study
Guzman, Daniel E., Sun, Yifei , Bertoni, Alan, Johnson, W. Craig , Watson, Karol E., Hoffman, E.A., Dubin, Robert , Oelsner, Elizabeth C. , Laine, Andrew F. , Ortega, Victor E. , Oelsner, Elizabeth C , Pottinger, Tess D. , Post, Wendy S. , Allen, Norrina B. , Pankow, James S. , Manichaikul, Ani , Dubin, R., Deo, Rajat , Angelini, Elsa D. , Bowler, Russell P. , Ganz, Peter , Barr, R. Graham

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5009-A5009

10.1164/ajrccm.2025.211.abstracts.a5009 Get It

Abstract Chronic obstructive pulmonary disease (COPD) and pulmonary emphysema were the third-leading cause of death globally in 2019. Besides alpha-1 antitrypsin deficiency, emphysema lacks disease-modifying medications due to its heterogeneity and there remains a need to further investigate emphysema subtypes to advance its diagnosis and treatment. Recent unsupervised machine learning of the texture and anatomical location of emphysema on computed tomography (CT) images of the lung defined six quantitative CT emphysema subtypes uniquely associated with specific gene variants, environmental exposures, symptoms, physiology and clinical events. We aim to identify associations of plasma proteins with each CT emphysema subtype cross-sectionally in a multi-ethnic general population sample. MESA is a prospective cohort study that recruited 6,814 participants from six communities who self-identified as White, Black, Hispanic, or Asian race/ethnicity, ages 45-84 years old and free of clinical cardiovascular disease in 2000-02. The MESA Lung Study performed CT scans among 3,137 participants in 2010-12, which were labeled with previously described (PMID: 37268414) CT emphysema subtypes. Proteomics was assessed using SomaScan version 4.1 assay (7,596 plasma proteins). Linear regression models were adjusted for age, height, weight, sex, race, educational attainment, smoking status, pack years, urine cotinine level, body-mass index (BMI), estimated glomerular filtration rate (eGFR), CT scanner manufacturer and other CT emphysema subtypes. Results were adjusted to reflect a False Discovery Rate (FDR) p-value of less than 5% using the Benjamini-Hochberg method. Among 2,343 participants with both CT and proteomic data (mean age 69.5 years, 52.3% women, 23.7% with COPD), we identified statistically significant associations of proteins with the vanishing lung subtype (42 proteins; top hit Natural cytotoxicity triggering receptor 3 ligand 1, q = 2.9[asterisk]10-9), restrictive combined pulmonary fibrosis/emphysema (CPFE) subtype (11 proteins; top hit Integrin alpha-2/b1, q=1.0[asterisk]10-5), the combined bronchitis-apical emphysema subtype (9 proteins; top hit Desmoglein-2, q=8.8[asterisk]10-13), and the diffuse emphysema subtype (4 proteins; top hit Pulmonary surfactant-associated protein D, q=5.7[asterisk]10-3). No significant proteins were associated with the obstructive CPFE or senile subtypes after FDR correction. Most proteins were uniquely associated with one CT emphysema subtype, while a few proteins were associated with more than one subtype. This study identified specific proteins for different CT emphysema subtypes, many of which have been related less specifically to emphysema, including pulmonary surfactant production, anti-inflammatory pathways, and mitochondrial deregulation, amongst others. Validation of these proteomic associations can provide insight into further pathway assessment, clinical biomarker discovery, and targeted prevention of emphysema in the general population.
Association of Contrast Enhanced Dual Energy CT-derived Pulmonary Arterial Tree-to-Lung Ratio (ArtLR) With COPD
Newcomb, Nora , Dunn, Melissa S., Guo, J. , Comellas, A.P., Woodruff, P., Curtis, J.L., Hansel, Nadia N. , Han, M.K. , Hoffman, E.A., Hosseini, S., Orr, J., Dunn, M., Leininger, J., Gerard, Sarah E. , Comellas, A.P., Jacob, Mathews , schroeder, J., Curtis, J.L., Reinhardt, Joseph M. , Hermann, E.A. , Barr, R. Graham , Smith, Benjamin M. , Hoffman, E.A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5007-A5007

10.1164/ajrccm.2025.211.abstracts.a5007 Get It

Abstract RATIONALE: Airway-to-lung ratio (AirLR), calculated as the mean of airway lumen diameters at standard anatomic locations divided by the cube-root of total lung volume, is associated with COPD risk regardless of smoking status, and we have previously shown an association between total-pulmonary-vascular-volume-to-lung-size relationship with AirLR. [PMCID: PMC11284327] Using dual energy computed tomography (DECT), we recently developed a deep learning-based algorithm for pulmonary arterial segmentation to compute pulmonary-arterial-to-lung ratio (ArtLR) which correlated significantly with AirLR and markers COPD. Here we automate image processing in a larger cohort to estimate ArtLR, introduce an alternative ArtLR standardization and correlate it to COPD-related measures of lung structure and function. METHODS: Using a SPIROMICS sub-cohort (110 participants), imaged via contrast enhanced DECT at functional residual capacity (FRC), an automatic deep learning pipeline segmented the arteries from the pulmonary vascular tree. Another pipeline automatically extracted the centerlines and calculated average arterial segment diameters. A paired non-contrast total lung capacity (TLC) scan was registered to the DECT FRC scan to transfer airway segment labels from the TLC to FRC domain. AirLR was calculated as the mean of airway lumen diameters at standard anatomic locations (trachea-to-subsegments) divided by cube root of lung volume [TLC or FRC]. A simple Long Short-Term Memory (LSTM) network was used to find corresponding anatomic arterial segments. Associations between ArtLR and %Emphysema, AirLR, pre- and post-bronchodilator FEV1/FVC, and a texture-based (AMFM) measure of %broncho-vascular bundles was assessed using linear regression to adjust for age, sex and BMI. RESULTS: In adjusted analyses, a 1-SD decrement in ArtLR-TLC was associated with 4.198 units increase in %Emphysema-910 (95%CI: 1.360-7.037; p = 0.0041), and 0.8198 units decrease in %Bronchovascular (95%CI: 0.5037-1.136; p < 0.0001). A 1-SD increment in ArtLR-TLC was associated with 0.2515 SD increase in AirLR-Outer (95%CI: 0.04947SD-0.4536SD; p = 0.0152), and 0.02083 units increase in PreBronch-FEV1FVC (95%CI: 0.001814-0.03984; p = 0.0321). Sex and BMI show significant associations with ArtLR-TLC, where female is associated with 1.068 SD decrease in ArtLR, and a unit increase in BMI is associated with 0.05788 SD increase in ArtLR (both p-values < 0.0001), and age was not association with ArtLR. CONCLUSIONS: An automated pipeline for pulmonary arterial tree segmentation and standardization from contrast enhanced DECT FRC scans demonstrates a significant relationship between ArtLR and AirLR as well as between ArtLR and %emphysema, and FEV1/FVC. A standardized method of arterial tree size assessment provides for expanded exploration of vascular vs airway disease etiologies.